These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17509095)

  • 1. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome.
    Frissora CL; Cash BD
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1271-81. PubMed ID: 17509095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
    Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin for the treatment of irritable bowel syndrome.
    Cremonini F; Lembo A
    Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
    Kane JS; Ford AC
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin treatment for symptoms of irritable bowel syndrome.
    Fumi AL; Trexler K
    Ann Pharmacother; 2008 Mar; 42(3):408-12. PubMed ID: 18303148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Sultan S; Chang L; Heidelbaugh JJ; Smalley W; Verne GN
    Gastroenterology; 2022 Jul; 163(1):137-151. PubMed ID: 35738725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
    Schey R; Rao SS
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
    Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of irritable bowel syndrome and an update on therapeutic approaches.
    Bassett JT; Cash BD
    Expert Opin Pharmacother; 2008 May; 9(7):1129-43. PubMed ID: 18422471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic treatment may ease symptoms of irritable bowel syndrome.
    Mayo Clin Womens Healthsource; 2011 Jun; 15(6):3. PubMed ID: 21540786
    [No Abstract]   [Full Text] [Related]  

  • 19. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irritable bowel syndrome].
    Musch A
    Med Monatsschr Pharm; 2006 Oct; 29(10):378-9. PubMed ID: 17058897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.